Sign in

Covid-19: ICMR studying reinfections; identifies 3 cases

A recent study, which is published in the journal Lancet Infectious Diseases, has found that reinfection could occur in Covid-19 patients, and the symptoms would likely to be more severe following the relapse of the viral infection

Updated on: Oct 14, 2020, 10:30:01 IST
Hindustan Times, New Delhi | By
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

The Indian Council of Medical Research (ICMR), which is studying reinfection among coronavirus (Covid-19) cases, has identified three to date that are being looked into, said Dr Balram Bhargava, director-general (D-G), ICMR, on Tuesday.

ICMR director-general Dr Balram Bhargava said cases of reinfection include two in Mumbai. (File photo)
ICMR director-general Dr Balram Bhargava said cases of reinfection include two in Mumbai. (File photo)

“We are studying the reinfection cases. So far, three such cases have been reported; two from Mumbai and one from Ahmedabad. There are various cut-off days that are being referred to for reinfection. Though the public is going by up to 110 days, we are taking 100 as the cut-off period because the antibodies last until then,” said Dr Bhargava.

Also read: Nevada man experienced severe symptoms during second bout of illness

A recent study, which is published in the journal Lancet Infectious Diseases, has found that reinfection could occur in Covid-19 patients, and the symptoms would likely to be more severe following the relapse of the viral infection.

“The World Health Organisation (WHO) has documented about two dozen cases of Covid-19 reinfection. We have established telephonic contact with the three cases of reinfection as part of our study. They are being looked into,” he added.

On Sunday, Union minister for health and family welfare Dr Harsh Vardhan had also said that the ICMR had set up a committee of experts to study reported cases of reinfection among Covid-19 patients.

“The ICMR has commissioned a study to look into the cases of reinfection in the country. However, their results are still awaited,” the minister had said while responding to queries from the public on social media as part of the fifth episode of his Sunday Samvaad programme.

Dr Bhargava said though SARS-CoV-2, which causes Covid-19, was found to be mutating, the changes were negligible.

“They will have no impact on the effectiveness of the Covid-19 vaccine that is under various stages of development in several countries around the world. Major changes, which will have a bearing on vaccine efficacy, take up to 15 years and are called antigenic shifts. A minor antigenic drift is being reported,” he added.

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More